Background CT-P13 was developed as a biosimilar product to infliximab (Remicade;), a chimeric monoclonal antibody approved in the European Union in 1999 for the treatment of rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, and psoriatic arthritis. ...
Newer drugs attempt to suppress only one small part of the immune system, not all of it. For example, drugs like Enbrel and Remicade block tumor necrosis factor. This is a protein that causes inflammation, a physical reaction to infection, injury or other causes. These drugs have been useful...